Published 2 years ago

Pfizer oral COVID-19 pill gets U.S. authorization for at-home use

Summary by Wall Street Journal

The FDA cleared use of Pfizer’s Paxlovid pill, the first Covid-19 drug that newly infected patients can now take at home to stay out of the hospital.

0 Articles

All

Left

Center

Right

News18 India

Pfizer Pill Becomes First US-authorized Home Covid-19 Treatment

The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited.

2 years ago·India

Read Full Article

The Guardian

FDA authorizes antiviral pill as first approved at-home treatment for Covid

Data from Pfizer’s clinical trial showed two-drug antiviral regimen was 90% effective in preventing hospitalizations and deaths in high-risk patients

2 years ago·London, United Kingdom

Read Full Article

The Hindu

Pfizer pill ‘Paxlovid’ becomes first US-authorized home COVID treatment

The pill has mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severe disease

2 years ago·India

Read Full Article

CTV News

Pfizer pill becomes 1st U.S.-authorized home COVID-19 treatment

U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

2 years ago·Canada

Read Full Article

The Independent

FDA authorises use of Pfizer-made pill to treat Covid-19

The pill will be available by prescription to eligible patients

2 years ago·London, United Kingdom

Read Full Article

Reuters

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for people ages 12 and older at risk of severe illness, the first oral and at-home treatment as well as a new tool against the fast-spreading Omicron variant.

2 years ago·United Kingdom

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.